|
시장보고서
상품코드
1679415
뉴클레오티드 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 기술별, 용도별, 지역별, 부문별 예측(2025-2030년)Nucleotide Market Size, Share & Trends Analysis Report By Product (Deoxy Nucleotides), By Technology (TaqMan Allelic Discrimination, Gene Chips & Microarrays), By Application, By Region, And Segment Forecasts, 2025 - 2030 |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
뉴클레오티드 시장 성장과 동향
Grand View Research, Inc.의 최신 보고서에 따르면, 세계 뉴클레오티드 시장 규모는 2025-2030년 동안 연평균 8.6%의 성장률을 기록하여 2030년에는 15억 2,000만 달러에 달할 것으로 예상됩니다.
세계 뉴클레오티드 시장은 제약 및 식음료 산업에서 널리 사용되고 있어 예측 기간 동안 큰 폭의 성장이 예상됩니다. 진단 연구 및 제약 응용 분야는 면역력 강화, 장 건강, 스트레스 회복에 긍정적인 영향을 미치는 특성으로 인해 뉴클레오티드 시장을 주도하고 있습니다. 또한, 가축 영양을 위한 효모 유래 뉴클레오티드와 함께 전 세계적으로 식품 뉴클레오티드 부문의 연구 개발이 확대되고 있으며, 이는 예측 기간 동안 수요를 촉진할 것으로 예상됩니다.
뉴클레오티드 시장 보고서 하이라이트
- TaqMan 대립유전자 식별 부문이 2024년 세계 시장을 장악했으며, 파이로 시퀀싱을 통한 SNP가 그 뒤를 이었습니다.
- 진단 연구 부문이 2024년 뉴클레오티드 세계 시장을 장악했습니다.
- 디옥시뉴클레오티드(dNTPs) 부문은 2024년 48.4%의 매출 점유율로 세계 뉴클레오티드 시장을 장악했으며, 예측 기간 동안 가장 빠른 CAGR로 확대될 가능성이 높습니다.
- 북미 뉴클레오티드 시장은 2024년 38.9%의 최대 시장 점유율을 확보했으며, 유럽 뉴클레오티드 시장은 2025-2030년까지 8.4%의 CAGR로 급성장할 것으로 예상됩니다.
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 뉴클레오티드 시장 변수, 동향, 범위
- 시장 계통 전망
- 시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
- 비즈니스 환경 분석
- 산업 분석 - Porter's Five Forces 분석
- PESTLE 분석
제4장 뉴클레오티드 시장 : 제품 비즈니스 분석
- 제품 시장 점유율, 2024년과 2030년
- 제품 부문 대시보드
- 시장 규모와 예측과 동향 분석, 제품별, 2018-2030년
- 데옥시 뉴클레오티드
- 디데옥시 뉴클레오티드
- RNA 합성용 뉴클레오티드(rNTP)
- 표지 뉴클레오티드
제5장 뉴클레오티드 시장 : 기술 비즈니스 분석
- 기술 시장 점유율, 2024년과 2030년
- 기술 부문 대시보드
- 시장 규모와 예측과 동향 분석, 기술별, 2018-2030년
- TaqMan 대립 유전자 식별
- 유전자 칩과 마이크로어레이
- 파이로시퀀싱에 의한 SNP
- 기타
제6장 뉴클레오티드 시장 : 용도 비즈니스 분석
- 용도 시장 점유율, 2024년과 2030년
- 용도 부문 대시보드
- 시장 규모와 예측과 동향 분석, 용도별, 2018-2030년
- 의약품
- 진단 조사
- 식품 및 음료 첨가물
- 동물 사료첨가물
- 기타
제7장 뉴클레오티드 시장 : 지역별, 추정·동향 분석
- 지역별 시장 점유율 분석, 2024년과 2030년
- 지역별 시장 대시보드
- 시장 규모, 예측 동향 분석, 2018-2030년
- 북미
- 미국
- 캐나다
- 멕시코
- 유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
- 아시아태평양
- 일본
- 중국
- 인도
- 호주
- 태국
- 한국
- 라틴아메리카
- 브라질
- 아르헨티나
- 중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트
제8장 경쟁 구도
- 참여자 개요
- 기업의 시장 포지션 분석
- 기업 분류
- 전략 매핑
- 기업 개요/상장 기업
- CJ CheilJedang Corp.
- Star Lake Bioscience
- Thermo Fisher Scientific Inc.
- MEIHUA HOLDINGS GROUP CO., LTD.
- F. Hoffmann-La Roche Ltd.
- Biorigin
- DSM
- Promega Corporation
- Agilent Technologies, Inc.
- Lallemand Inc.
- Nanjing BIoTogether Co., Ltd.
- NuEra Nutraceuticals Inc.
- Ohly
Nucleotide Market Growth & Trends:
The global nucleotide market size is expected to reach USD 1.52 billion by 2030, registering a CAGR of 8.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. The global nucleotide market is expected to witness substantial growth over the forecast period owing to its widespread use in pharmaceuticals and food & beverage industries. Diagnostic research along with pharmaceutical applications dominated the nucleotide market owning to properties including enhanced immunity, positive effects on the intestines, and positive effects of recovery from stress. In addition, growing R&D in the field of dietary nucleotide coupled with yeast-derived nucleotide for livestock nutrition across the globe is expected to propel demand over the forecast period.
Nucleotide Market Report Highlights:
- The TaqMan allelic discrimination segment dominated the global market in 2024, followed by SNP by pyrosequencing
- The diagnostics research segment dominated the global market for nucleotides in 2024
- The deoxy nucleotides (dNTPs) segment dominated the global nucleotide market in 2024 with a revenue share of 48.4% and is furthermore likely to expand with the fastest CAGR over the forecast period
- North America nucleotide market secured the largest market share of 38.9% in 2024 and Europe nucleotide market is set to expand at the fastest-growing CAGR of 8.4% from 2025 to 2030
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Technology
- 1.2.3. Application
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Nucleotide Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrant
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
Chapter 4. Nucleotide Market: Product Business Analysis
- 4.1. Product Market Share, 2024 & 2030
- 4.2. Product Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, By Product, 2018 to 2030 (USD Million)
- 4.4. Deoxy Nucleotides
- 4.4.1. Deoxy Nucleotides Market, 2018 - 2030 (USD Million)
- 4.4.1.1. Enzyme Sourced
- 4.4.1.1.1. Enzyme Sourced Nucleotides Market, 2018 - 2030 (USD Million)
- 4.4.1.2. Chemical Synthesis
- 4.4.1.2.1. Chemical Synthesis Nucleotides Market, 2018 - 2030 (USD Million)
- 4.4.1.1. Enzyme Sourced
- 4.4.1. Deoxy Nucleotides Market, 2018 - 2030 (USD Million)
- 4.5. Dideoxynucleotides
- 4.5.1. Dideoxynucleotides Market, 2018 - 2030 (USD Million)
- 4.6. Nucleotides for RNA Synthesis (rNTP)
- 4.6.1. Nucleotides for RNA Synthesis (rNTP) Market, 2018 - 2030 (USD Million)
- 4.7. Labelled Nucleotides
- 4.7.1. Labelled Nucleotides Market, 2018 - 2030 (USD Million)
Chapter 5. Nucleotide Market: Technology Business Analysis
- 5.1. Technology Market Share, 2024 & 2030
- 5.2. Technology Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, By Technology, 2018 to 2030 (USD Million)
- 5.4. TaqMan Allelic Discrimination
- 5.4.1. TaqMan Allelic Discrimination Market, 2018 - 2030 (USD Million)
- 5.5. Gene Chips & Microarrays
- 5.5.1. Gene Chips & Microarrays Market, 2018 - 2030 (USD Million)
- 5.6. SNP by Pyrosequencing
- 5.6.1. Gene Chips & Microarrays Market, 2018 - 2030 (USD Million)
- 5.7. Others
- 5.7.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. Nucleotide Market: Application Business Analysis
- 6.1. Application Market Share, 2024 & 2030
- 6.2. Application Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, By Application, 2018 to 2030 (USD Million)
- 6.4. Pharmaceuticals
- 6.4.1. Pharmaceuticals Market, 2018 - 2030 (USD Million)
- 6.5. Diagnostics Research
- 6.5.1. Diagnostics Research Market, 2018 - 2030 (USD Million)
- 6.6. Food & Beverage Additive
- 6.6.1. Food & Beverage Additive Market, 2018 - 2030 (USD Million)
- 6.7. Animal Feed Additive
- 6.7.1. Animal Feed Additive Market, 2018 - 2030 (USD Million)
- 6.8. Others
- 6.8.1. Others Market, 2018 - 2030 (USD Million)
Chapter 7. Nucleotide Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2024 & 2030
- 7.2. Regional Market Dashboard
- 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 7.4. North America
- 7.4.1. North America Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamic
- 7.4.2.2. Regulatory Framework
- 7.4.2.3. Competitive Insights
- 7.4.2.4. U.S. Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamic
- 7.4.3.2. Regulatory Framework
- 7.4.3.3. Competitive Insights
- 7.4.3.4. Canada Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. Mexico
- 7.4.4.1. Key Country Dynamic
- 7.4.4.2. Regulatory Framework
- 7.4.4.3. Competitive Insights
- 7.4.4.4. Mexico Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5. Europe
- 7.5.1. Europe Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. UK
- 7.5.2.1. Key Country Dynamic
- 7.5.2.2. Regulatory Framework
- 7.5.2.3. Competitive Insights
- 7.5.2.4. UK Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Germany
- 7.5.3.1. Key Country Dynamic
- 7.5.3.2. Regulatory Framework
- 7.5.3.3. Competitive Insights
- 7.5.3.4. Germany Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.4. France
- 7.5.4.1. Key Country Dynamic
- 7.5.4.2. Regulatory Framework
- 7.5.4.3. Competitive Insights
- 7.5.4.4. France Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.5. Italy
- 7.5.5.1. Key Country Dynamic
- 7.5.5.2. Regulatory Framework
- 7.5.5.3. Competitive Insights
- 7.5.5.4. Italy Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.6. Spain
- 7.5.6.1. Key Country Dynamic
- 7.5.6.2. Regulatory Framework
- 7.5.6.3. Competitive Insights
- 7.5.6.4. Spain Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.7. Denmark
- 7.5.7.1. Key Country Dynamic
- 7.5.7.2. Regulatory Framework
- 7.5.7.3. Competitive Insights
- 7.5.7.4. Denmark Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.8. Sweden
- 7.5.8.1. Key Country Dynamic
- 7.5.8.2. Regulatory Framework
- 7.5.8.3. Competitive Insights
- 7.5.8.4. Sweden Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.9. Norway
- 7.5.9.1. Key Country Dynamic
- 7.5.9.2. Regulatory Framework
- 7.5.9.3. Competitive Insights
- 7.5.9.4. Norway Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. Japan
- 7.6.2.1. Key Country Dynamic
- 7.6.2.2. Regulatory Framework
- 7.6.2.3. Competitive Insights
- 7.6.2.4. Japan Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. China
- 7.6.3.1. Key Country Dynamic
- 7.6.3.2. Regulatory Framework
- 7.6.3.3. Competitive Insights
- 7.6.3.4. China Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. India
- 7.6.4.1. Key Country Dynamic
- 7.6.4.2. Regulatory Framework
- 7.6.4.3. Competitive Insights
- 7.6.4.4. India Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. Australia
- 7.6.5.1. Key Country Dynamic
- 7.6.5.2. Regulatory Framework
- 7.6.5.3. Competitive Insights
- 7.6.5.4. Australia Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.6. Thailand
- 7.6.6.1. Key Country Dynamic
- 7.6.6.2. Regulatory Framework
- 7.6.6.3. Competitive Insights
- 7.6.6.4. Thailand Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.7. South Korea
- 7.6.7.1. Key Country Dynamic
- 7.6.7.2. Regulatory Framework
- 7.6.7.3. Competitive Insights
- 7.6.7.4. South Korea Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7. Latin America
- 7.7.1. Latin America Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamic
- 7.7.2.2. Regulatory Framework
- 7.7.2.3. Competitive Insights
- 7.7.2.4. Brazil Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamic
- 7.7.3.2. Regulatory Framework
- 7.7.3.3. Competitive Insights
- 7.7.3.4. Argentina Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamic
- 7.8.2.2. Regulatory Framework
- 7.8.2.3. Competitive Insights
- 7.8.2.4. South Africa Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key Country Dynamic
- 7.8.3.2. Regulatory Framework
- 7.8.3.3. Competitive Insights
- 7.8.3.4. Saudi Arabia Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.4. UAE
- 7.8.4.1. Key Country Dynamic
- 7.8.4.2. Regulatory Framework
- 7.8.4.3. Competitive Insights
- 7.8.4.4. UAE Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.5. Kuwait
- 7.8.5.1. Key Country Dynamic
- 7.8.5.2. Regulatory Framework
- 7.8.5.3. Competitive Insights
- 7.8.5.4. Kuwait Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Participant Overview
- 8.2. Company Market Position Analysis
- 8.3. Company Categorization
- 8.4. Strategy Mapping
- 8.5. Company Profiles/Listing
- 8.5.1. CJ CheilJedang Corp.
- 8.5.1.1. Participant's Overview
- 8.5.1.2. Financial Performance
- 8.5.1.3. Product Benchmarking
- 8.5.1.4. Strategic Initiatives
- 8.5.2. Star Lake Bioscience
- 8.5.2.1. Participant's Overview
- 8.5.2.2. Financial Performance
- 8.5.2.3. Product Benchmarking
- 8.5.2.4. Strategic Initiatives
- 8.5.3. Thermo Fisher Scientific Inc.
- 8.5.3.1. Participant's Overview
- 8.5.3.2. Financial Performance
- 8.5.3.3. Product Benchmarking
- 8.5.3.4. Strategic Initiatives
- 8.5.4. MEIHUA HOLDINGS GROUP CO., LTD.
- 8.5.4.1. Participant's overview
- 8.5.4.2. Financial Performance
- 8.5.4.3. Product Benchmarking
- 8.5.4.4. Strategic Initiatives
- 8.5.5. F. Hoffmann-La Roche Ltd.
- 8.5.5.1. Participant's Overview
- 8.5.5.2. Financial Performance
- 8.5.5.3. Product Benchmarking
- 8.5.5.4. Strategic Initiatives
- 8.5.6. Biorigin
- 8.5.6.1. Participant's Overview
- 8.5.6.2. Financial Performance
- 8.5.6.3. Product Benchmarking
- 8.5.6.4. Strategic Initiatives
- 8.5.7. DSM
- 8.5.7.1. Participant's Overview
- 8.5.7.2. Financial Performance
- 8.5.7.3. Product Benchmarking
- 8.5.7.4. Strategic Initiatives
- 8.5.8. Promega Corporation
- 8.5.8.1. Participant's Overview
- 8.5.8.2. Financial Performance
- 8.5.8.3. Product Benchmarking
- 8.5.8.4. Strategic Initiatives
- 8.5.9. Agilent Technologies, Inc.
- 8.5.9.1. Participant's Overview
- 8.5.9.2. Financial Performance
- 8.5.9.3. Product Benchmarking
- 8.5.9.4. Strategic Initiatives
- 8.5.10. Lallemand Inc.
- 8.5.10.1. Participant's Overview
- 8.5.10.2. Financial Performance
- 8.5.10.3. Product Benchmarking
- 8.5.10.4. Strategic Initiatives
- 8.5.11. Nanjing Biotogether Co., Ltd.
- 8.5.11.1. Participant's Overview
- 8.5.11.2. Financial Performance
- 8.5.11.3. Product Benchmarking
- 8.5.11.4. Strategic Initiatives
- 8.5.12. NuEra Nutraceuticals Inc.
- 8.5.12.1. Participant's Overview
- 8.5.12.2. Financial Performance
- 8.5.12.3. Product Benchmarking
- 8.5.12.4. Strategic Initiatives
- 8.5.13. Ohly
- 8.5.13.1. Participant's Overview
- 8.5.13.2. Financial Performance
- 8.5.13.3. Product Benchmarking
- 8.5.13.4. Strategic Initiatives
- 8.5.1. CJ CheilJedang Corp.
